Arbutus Biopharma (ABUS) Accumulated Depreciation & Amortization (2016 - 2025)
Arbutus Biopharma (ABUS) has disclosed Accumulated Depreciation & Amortization for 16 consecutive years, with $213000.0 as the latest value for Q4 2025.
- Quarterly Accumulated Depreciation & Amortization fell 98.36% to $213000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $213000.0 through Dec 2025, down 98.36% year-over-year, with the annual reading at $213000.0 for FY2025, 98.36% down from the prior year.
- Accumulated Depreciation & Amortization hit $213000.0 in Q4 2025 for Arbutus Biopharma, down from $352000.0 in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $13.0 million in Q4 2024 to a low of $213000.0 in Q4 2025.
- Historically, Accumulated Depreciation & Amortization has averaged $2.8 million across 5 years, with a median of $744000.0 in 2022.
- Biggest five-year swings in Accumulated Depreciation & Amortization: grew 23.0% in 2021 and later crashed 98.36% in 2025.
- Year by year, Accumulated Depreciation & Amortization stood at $9.4 million in 2021, then grew by 15.22% to $10.8 million in 2022, then rose by 10.17% to $11.9 million in 2023, then grew by 9.21% to $13.0 million in 2024, then plummeted by 98.36% to $213000.0 in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for ABUS at $213000.0 in Q4 2025, $352000.0 in Q3 2025, and $341000.0 in Q2 2025.